Manufacturing

Feliza Mirasol is the science editor for 

Articles

Further development of nucleic acid-based therapeutics has been accelerated by the recent success of mRNA vaccines.

Shining a Spotlight on Nucleic Acid-Based Therapeutics

Complex hurdles complicate the development of emerging therapies.

Emerging Therapies Face Development Hurdles

Plant-based manufacturing technology gains mainstream edge in biopharmaceutical production.

Emerging Plant-based Platform for Biomanufacturing

Catalent will invest $350 million into integrated biologics drug substance and drug product manufacturing at Bloomington, Indiana facility.

Catalent to Invest $350 Million in Manufacturing Facility in Bloomington, Indiana

The recent success of mRNA vaccines has opened the door for further and future development of nucleic acid-based therapies.

Nucleic Acid-based Therapeutics Are Stepping into the Spotlight

Spectrum Chemical has further expanded its bioCERTIFIED product portfolio to support the growing global demand for new vaccines and therapeutics. 

Spectrum Chemical Announces Expansion of bioCERTIFIED Product Portfolio to Support Global Demand for New Vaccines and Therapeutics 

The use of bioengineering offers practical tools for the evolution of host cells.

Outlining Cell Lines’ Future with Engineering Approaches

Capacity concerns and regulatory compliance considerations will drive the decision about outsourcing the manufacture of clinical trial materials.

Insights into Outsourced vs. In-house Clinical Trial Services

Recipharm has strengthened its biologics manufacturing capabilities with the acquisition of both Vibalogics and Arranta Bio.

Recipharm Acquires Two Biologics CDMOs: Vibalogics and Arranta Bio

Thermo Fisher Scientific is expanding its Millersburg, Penn., site with a $40 million investment to support increased production of single-use technology for critical vaccines and biologics.

Manufacturing, Biologics